Archibald G Prentice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Archibald G Prentice has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aoife Molloy
Department of Medical Microbiology, Royal Free Hospital, Pond Street, NW3 2QG, London, UK
2 shared publications - Christopher C Kibbler
Department of Medical Microbiology, Royal Free Hospital, Pond Street, NW3 2QG, London, UK
2 shared publications - Giuseppe Ippolito
Unicamillus International Medical University, Rome, Italy
2 shared publications - Simone Lanini
Infectious Diseases Clinic, Department of Medicine (DAME), University of Udine , Udine
2 shared publications - Paul E. M. Fine
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
1 shared publication
Latest Publications
- Open Access
- 12 July 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 317
Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study
Rituximab (R) is a chimeric human-murine anti-CD20 monoclonal antibody used to treat B-cell lymphomas. Despite R remarkable activity against malignant cells, there are concerns that R may facilitate the occurrence of infections. This study is aimed to define risk factors for infections, and the potential interaction with time since therapy, in patients undergoing R containing regimens. The study has been designed as a multiple failure events historical cohort including all patients who received a R contain regimen at London Royal Free Hospital between May 2007 and April 2009. One-hundred-eighty-one infections occurred among the 113 enrolled patients (overall incidence rate 3.30 per 1000 person-days). Multivariate analysis showed that lymphocyte counts at nadir, graft versus host disease, HIV sero-status and the type of malignancy were all independently associated with the risk of infection. In addition the analysis of the interaction with the time since the start of therapy provided evidence that different risk factors may increase risk of infections in different times. This study provides preliminary data to describe the association between several patients’ baseline characteristics and infections during therapy with R.
- 12 July 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 317
Open AccessInfections in patients taking Rituximab for hematologic malignancies: two-year cohort study
Rituximab (R) is a chimeric human-murine anti-CD20 monoclonal antibody used to treat B-cell lymphomas. Despite R remarkable activity against malignant cells, there are concerns that R may facilitate the occurrence of infections. This study is aimed to define risk factors for infections, and the potential interaction with time since therapy, in patients undergoing R containing regimens. The study has been designed as a multiple failure events historical cohort including all patients who received a R contain regimen at London Royal Free Hospital between May 2007 and April 2009. One-hundred-eighty-one infections occurred among the 113 enrolled patients (overall incidence rate 3.30 per 1000 person-days). Multivariate analysis showed that lymphocyte counts at nadir, graft versus host disease, HIV sero-status and the type of malignancy were all independently associated with the risk of infection. In addition the analysis of the interaction with the time since the start of therapy provided evidence that different risk factors may increase risk of infections in different times. This study provides preliminary data to describe the association between several patients’ baseline characteristics and infections during therapy with R.
- Open Access
- 12 April 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 36
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-analysis were performed to determine whether or not the addition of R to C may increase the risk of severe infections in adults undergoing induction therapy for CD20+ ML.
- 12 April 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 36
Open AccessRisk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-analysis were performed to determine whether or not the addition of R to C may increase the risk of severe infections in adults undergoing induction therapy for CD20+ ML.